All In Biotech

NDA 208065 · Astrazeneca

Tagrisso

Osimertinib Mesylate · Oral · Kinase Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Nov 13, 2015

Approved uses

10

Original approval plus efficacy supplements

Registered trials

315

53 Phase 3, 82 recruiting

FAERS reports

33,148

31,031 serious, 14,432 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 14, 2026.

TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.2 , 2.2 ) • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.3 , 2.2 ) • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.4 , 2.2 ) • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. ( 1.5 , 2.2 ) 1.1 Adjuvant Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC TAGRISSO is indicated for the treatment of adult...

Mechanism: Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type. Two pharmacologically-active metabolites (AZ7550 and AZ5104 circulating at approximately 10% of the parent) with similar inhibitory profiles to osimertinib have been identified in the plasma after oral administration of osimertinib. AZ7550 showed a similar potency to osimertinib, while AZ5104 showed greater potency against exon 19 deletion and T790M mutants...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 14, 2026 Supplement 35 · Efficacy OrphanLetterLabel
  • Sep 25, 2024 Supplement 33 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
  • Feb 16, 2024 Supplement 30 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jan 31, 2024 Supplement 29 · Efficacy OrphanLetterLabel
  • Dec 18, 2020 Supplement 21 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Dec 9, 2020 Supplement 18 · Efficacy OrphanLabelLetter
  • May 23, 2020 Supplement 16 · Efficacy LetterLabel
  • Apr 18, 2018 Supplement 8 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Mar 30, 2017 Supplement 6 · Efficacy · priority review OrphanLabelLetter
  • Nov 13, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanSummary ReviewLetterLabel
2 products under this application
  • TAGRISSO · OSIMERTINIB MESYLATE EQ 40MG BASE · TABLET, ORAL · Prescription
  • TAGRISSO · OSIMERTINIB MESYLATE EQ 80MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Osimertinib" as an intervention, any sponsor and status, largest first.

All 315 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death11,742
  • malignant neoplasm progression3,446
  • diarrhoea1,744
  • fatigue1,121
  • drug resistance1,112
  • rash988
  • off label use830
  • decreased appetite829
  • disease progression790
  • dyspnoea784
  • drug ineffective762
  • nausea747

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20141
201535
2016685
20171,070
20181,424
20192,252
20203,363
20213,455
20223,423
20234,350
20244,988
20254,204
20263,897

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tagrisso (Osimertinib Mesylate)

2024 spending

$1.63B

Beneficiaries

12,370

96,403 claims

Per beneficiary

$131,537

$553.43 per unit

View as table
YearSpending
2020$793,479,172
2021$913,265,970
2022$1,081,280,466
2023$1,231,962,204
2024$1,627,109,177

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 310 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.